U.S. markets closed

Reliq Health Technologies Inc. (RHT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.5700-0.0200 (-3.39%)
At close: 3:59PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5900
Open0.6000
Bid0.5700 x 0
Ask0.5800 x 0
Day's Range0.5700 - 0.6000
52 Week Range0.2000 - 0.9400
Volume337,850
Avg. Volume1,283,019
Market Cap94.739M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.0810
Earnings DateMar 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reliq Health Technologies, Inc. Announces Two New Orthopedic Practice Contracts in the US
      GlobeNewswire

      Reliq Health Technologies, Inc. Announces Two New Orthopedic Practice Contracts in the US

      HAMILTON, Ontario, April 13, 2021 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed two new contracts with Orthopedic Practices in Texas, leveraging its iUGO Care platform to enable Orthopedic Specialists to manage their chronic orthopedic and post-operative patients at home. “It is very gratifying to see our business in Texas accelerating so quickly as a result of the successful vaccine rollout in that State,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “The orthopedic specialty represents a new market segment for Reliq and we are already gaining significant traction in this space. Reliq will receive an average revenue of $50 USD per patient per month under these two new contracts. The Company remains on track to achieve profitability by the end of the current quarter, and continues to see increasing revenue growth month over month as our clients return to normal operations thanks to widespread vaccination of frontline healthcare workers and at risk patient populations in the US. We are steadily building momentum in terms of both new client acquisition and patient onboarding, and demand for our Care Management Services in particular has exceeded our expectations.” iUGO Care’s Orthopedic module can be used by Orthopedic Specialists to provide Remote Patient Monitoring (RPM), Chronic Care Management (CCM), Principal Care Management (PCM) and Behavioural Health Integration (BHI) services to chronic orthopedic patients at home. Using iUGO Care helps orthopedic patients improve health outcomes and reduce symptoms through increased medication adherence and compliance with prescribed physiotherapy exercises. iUGO Care also enables orthopedic patients to receive support for the depression and anxiety frequently experienced by individuals living with chronic pain and mobility issues. Reliq Health Reliq Health Technologies is a rapidly growing global telemedicine that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB. ON BEHALF OF THE BOARD“Dr. Lisa Crossley”CEO and Director For further information please contact: Company ContactInvestor Relations at ir@reliqhealth.com US Investor Relations ContactInvestor RelationsLytham Partners, LLCBen ShamsianNew York | Phoenix646-829-9701shamsian@lythampartners.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statements Regarding Forward Looking Information Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements". We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Reliq Health Technologies Inc. (the "Company") does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company's historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements. SOURCE: Reliq Health Technologies Inc.

    • Reliq Health Technologies, Inc. Announces New Contract with Orthopedic Practice in Texas
      GlobeNewswire

      Reliq Health Technologies, Inc. Announces New Contract with Orthopedic Practice in Texas

      HAMILTON, Ontario, April 07, 2021 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed a new contract with its first Orthopedic Practice in Texas and, in response to significant market demand, has expanded its iUGO Care platform to allow Orthopedic Specialists to manage their chronic orthopedic and post-operative patients at home. “As the vaccine rollout successfully proceeds in the United States, we are very pleased to see our clients moving forward with patient onboarding at a steadily increasing pace,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “Now that clinicians in the US are able to return their focus to proactive patient care, we’re experiencing significant new demand for deployment of our existing solutions as well as requests for new features. We are excited to launch our newest iUGO Care module, designed to support Orthopedic Specialists who want to monitor both their chronic patients (e.g. those living with rheumatoid arthritis, osteoarthritis, osteoporosis, etc.) and their post-operative patients at home. According to the CDC, there are over 5.7 Million arthritis patients in Texas alone, representing a large and growing new target market segment for Reliq. Using iUGO Care to provide Remote Patient Monitoring (RPM), Chronic Care Management (CCM), Principal Care Management (PCM) and Behavioural Health Integration (BHI) services to chronic orthopedic patients can help improve medication adherence, increase compliance with prescribed physiotherapy exercises and reduce the depression and anxiety often seen in chronic pain patients, significantly enhancing their quality of life.” Leveraging the existing Medicare and Medicaid billing codes, Orthopedic practices can generate over $500,000 per year in new billings by providing RPM, CCM, PCM and BHI services to their patients. Reliq expects to begin onboarding orthopedic patients under this contract in April, at an average revenue of $50 USD per patient per month. Reliq Health Reliq Health Technologies is a rapidly growing global telemedicine that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB. ON BEHALF OF THE BOARD“Dr. Lisa Crossley”CEO and Director For further information please contact: Company ContactInvestor Relations at ir@reliqhealth.com US Investor Relations ContactInvestor RelationsLytham Partners, LLCBen ShamsianNew York | Phoenix646-829-9701shamsian@lythampartners.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statements Regarding Forward Looking Information Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements". We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Reliq Health Technologies Inc. (the "Company") does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company's historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements. SOURCE: Reliq Health Technologies Inc.

    • GlobeNewswire

      NEXT SUPER STOCKS Addressing Multi-Billion Dollar Healthcare Markets: Tetra Bio-Pharma, Relay Medical, Skylight Health, Reliq HealthTech

      NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “LiveChats” on social media streams. Over 170,000 investors have participated in Wall Street Reporter’s livestream events in the past 30 days. Tetra Bio-Pharma (OTC: TBPMF) (TSX: TBP) CEO, Dr. Guy Chamberland: “Expecting to Launch 3 New Cannabinoid-Derived Drugs in 2022 - Addressing $200 Billion Market Opportunities” In a recent presentation at Wall Street Reporter’s NEXT SUPER STOCK livestream, Tetra BioPharma (OTC: TBPMF) CEO Dr. Guy Chamberland, shared TBPMF’s advanced pipeline of cannabinoid derived drugs targeting $200 billion addressable market opportunities including pain, inflammation, oncology, and sepsis. TBPMF boasts one of the most advanced pipelines of Cannabinoid-derived medicines, supported by the urgent need for non-opioid alternatives to treat pain and inflammation. Significantly, TBPMF’s portfolio of IP and patents is spearheaded by a team experienced at bringing new drugs to market. TBPMF now has 3 drugs in the advanced clinical stages, which it expects to bring to market in 2022: Quixleef targeting pain management, a $58 billion market opportunity, ARDS-003 immunomodulator which is a $132 billion market opportunity, and PPP-003 for ophthalmic inflammation indication - a $31 billion market. Compelling for investors, TBMPF has multiple near-term catalysts in place, and with a current valuation of about $50 million, TBPMF is trading at a just a small fraction of its peer group in the biotech space, with similar pipelines. Watch Tetra Bio-Pharma (OTC: TBPMF) Next Super Stock 3/18/21 video: https://bit.ly/3mjdoPL Relay Medical (CSE: RELA) (OTC: RYMDF) President Clark Kent: “AI Diagnostics Targeting Billion Dollar Healthcare Opportunities” In a recent presentation at Wall Street Reporter’s Investors Discovery Day livestream, Relay Medical Corp. (CSE: RELA) (OTC: RYMDF) President Clark Kent, discussed the company’s diagnostics and AI HealthTech focus, which targets multi-billion dollar opportunities in global healthcare markets. A highlight of the presentation was a video demo of the company’s rapid testing and tracking platform for infectious diseases, including COVID-19. The platform has already been successfully deployed in testing and tracking infectious disease outbreaks globally, including ebola and malaria. Watch Relay Medical (OTC: RYMDF) Investors Discovery Day Video: http://bit.ly/3aRwEzn March 25 - Relay Medical & Fio Commence COVID-19 Rapid Testing for U.S. Departing Passengers at Toronto Pearson Airport. Using the Fionet Platform, departing U.S. passengers can book their rapid test between 72 hours and 2.5 hours in advance of their flight departure time using their personal mobile device at gtaa.fiona rapidresponse.com. The testing program utilizes Fionet's high-throughput testing solution, including multiple mobile point-of-need devices connected in real-time to cloud data services, processing high quantities of rapid antigen tests per hour and capable of turning around test results within 20 minutes. The Fionet Platform will also manage passenger scheduling, rapid test processing, real-time results reporting, integration with LuminUltra PCR devices, Response Biomedical antigen rapid diagnostic tests (RDTs) and devices, Abbott Panbio antigen RDTs, and all corresponding data and messaging flows. Watch Relay Medical (OTC: RYMDF) Investors Discovery Day Video: http://bit.ly/3aRwEzn Skylight Health Group (TSX.V: SHG) (OTC: SHGFF) CEO, Prad Sekar: “Now At Inflection Point - Positioned for 10X Upside Revenue Growth Potential” Skylight Health Group (TSX.V: SHG) (OTC: SHGFF) was recently a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK livestream investor conference. CEO Prad Sekar, outlined his vision for building Skylight into a multi-billion dollar business focused on the highly fragmented US healthcare market. Skylight already operates 30 clinics, in 14 states, with virtual telehealth overlay, serving over 120,000 patients - and is one of the fastest growing multi-disciplinary health systems in the United States. Watch Skylight (OTC: SHGFF) Next Super Stock 3/4/21 video: http://bit.ly/3qAZAAr April 1, 12:30 EST - SHGFF is presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream. Click here to join:https://bit.ly/2PX0SpH Skyllight is now at an inflection point. SHGFF revenues are expected to be $56 million and $5.5 million EBITDA run rates, with a recently announced acquisition. SHGFF boasts a profitable base of operations, no long-term debt and cash balance of $10 million. In his presentation, Skylight CEO Prad Sekar, explains how the company can increase revenues organically by about 10X, as it optimizes clinics for profitability by expansion of services to the existing patient base, with it’s proven business model, stating: "$200 Million Revenues Run Rate in 2021 Is Goal". March 4 - SHGFF has entered into Letters of Intent (LOIs) to acquire 3 independent Primary Care practices in the United States, immediately adding over $10 million in revenue and positive EBITDA when closed. The transactions have a target closing price of between 4 – 5 x EBITDA which is consistent with the Company’s 5 recent transactions. The average purchase price for the combined assets averages below 1 x revenue. Watch Skylight (OTC: SHGFF) Next Super Stock 3/4/21 video: http://bit.ly/3qAZAAr April 1, 12:30 EST - SHGFF is presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream. Click here to join:https://bit.ly/2PX0SpH Reliq Health Technologies (OTC:RQHTF) (TSX.V:RHT) CEO Lisa Crossley: “2021 is Breakout Year for Our Telehealth Platform” In a recent presentation at Wall Street Reporter’s NEXT SUPER STOCK livestream, Reliq Health Technologies (OTC:RQHTF) CEO Lisa Crossley, explained how the company’s iUGO telehealth remote patient monitoring platform is now at an inflection point - with three significant new contracts announced, just in the past 30 days - and on path to $100 million revenues by 2024 (which could give RQHTF a valuation of $1 billion+ based on current peer group valuations). Reliq’s powerful iUGO telemedicine platform supports care coordination and community-based virtual healthcare, allows complex patients to receive high quality care at home, improving health outcomes, and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Watch Reliq Health Tech (OTC:RQHTF) (TSX.V:RHT) NEXT SUPER STOCK Video: https://bit.ly/3fneUPp March 16 - RQHTF announces new contract with a physician practice in Florida that provides clinical services to over 25 Skilled Nursing Facilities across the State. “We are very excited to be able to start onboarding new patients in Florida next month as the State begins to recover from the devastating effects of the global pandemic,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies. “Using the iUGO Care platform will enable the physicians who work with Skilled Nursing Facilities (SNFs) to offer post-discharge care to patients, reducing readmissions that result in significant financial penalties for SNFs. iUGO Care’s highly scalable Transitional Care Management (TCM), Remote Patient Monitoring (RPM), Chronic Care Management (CCM) and Behavioral Health Integration (BHI) solutions create new revenue streams for SNFs and physician practices and improve patient health outcomes and quality of life.” Watch Reliq Health Tech (OTC:RQHTF) (TSX.V:RHT) NEXT SUPER STOCK Video: https://bit.ly/3fneUPp WALL STREET REPORTER Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K About Wall Street Reporter’s Next Super Stock conference: Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/ CONTACT: WALL STREET REPORTER (212) 871-2057 ext 7 www.WallStreetReporter.com